| 肖青凤,吴 琰,史晓宁,钟 贞,苏志谦.不同剂量重组人生长激素治疗对特发性矮小症患儿骨代谢、甲状腺功能和血清Ghrelin、IGF-1水平的影响[J].,2021,(23):4569-4572 |
| 不同剂量重组人生长激素治疗对特发性矮小症患儿骨代谢、甲状腺功能和血清Ghrelin、IGF-1水平的影响 |
| Effects of Different Doses of Recombinant Human Growth Gormone on Bone Metabolism, Thyroid Function and Serum Levels of Ghrelin and IGF-1 in Children with Idiopathic Short Stature |
| 投稿时间：2021-04-06 修订日期：2021-04-28 |
| DOI：10.13241/j.cnki.pmb.2021.23.036 |
| 中文关键词: 重组人生长激素 特发性矮小症 骨代谢 甲状腺功能 Ghrelin IGF-1 |
| 英文关键词: Recombinant human growth hormone Idiopathic short stature Bone metabolism Thyroid function Ghrelin IGF-1 |
| 基金项目:湖南省中医药管理局一般项目（201668 ） |
|
| 摘要点击次数: 539 |
| 全文下载次数: 256 |
| 中文摘要: |
| 摘要 目的：探讨不同剂量重组人生长激素（rHGH）治疗对特发性矮小症（ISS）患儿骨代谢、甲状腺功能和血清食欲刺激素（Ghrelin）、胰岛素样生长因子-1（IGF-1）水平的影响。方法：选取2017年3月~2020年2月期间来我院接受治疗的ISS患儿60例，根据随机数字表法分为低剂量组（给予剂量0.10 U/kg?d进行治疗）和高剂量组（给予剂量0.20 U/kg?d进行治疗），各为30例。比较两组患儿生长发育情况[身高、体重、生长速度（GV）、身高标准积分（Ht SDS）]、骨代谢[骨碱性磷酸酶（BAP）、I型前胶原氨基端前肽（PINP）、I型胶原交联羧基末端肽（β-CTX）]、甲状腺功能[促甲状腺激素（TSH）、游离三碘甲腺原氨酸（FT3/sub>）、游离甲状腺素（FT4/sub>）]和血清Ghrelin、IGF-1水平。观察不良反应发生情况。结果：治疗1年后，高剂量组身高、体重、GV、Ht SDS高于低剂量组（P<0.05）。高剂量组治疗1年后BAP、PINP高于低剂量组，β-CTX低于低剂量组（P<0.05）。两组患儿治疗1年后TSH、FT3/sub>、FT4/sub>组内对比无统计学差异（P>0.05）。高剂量组Ghrelin低于低剂量组，IGF-1水平高于低剂量组（P<0.05）。两组总的不良反应发生率组间对比无统计学差异（P>0.05）。结论：相对于0.10 U/kg?d剂量的rHGH，0.20 U/kg?d剂量的rHGH可更好的促进ISS患儿生长发育，调节骨代谢和血清Ghrelin、IGF-1水平，且对人体甲状腺功能无影响。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of different doses of recombinant human growth hormone (rhGH) on bone metabolism, thyroid function and the levels of serum appetite stimulating hormone (Ghrelin) and insulin like growth factor-1 (IGF-1) in children with idiopathic short stature (ISS). Methods: 60 children with ISS who were treated in our hospital from March 2017 to February 2020 were selected, and according to random number table, they were divided into low-dose group (given 0.10 U/kg?d dose for treatment) and high-dose group (given 0.20 U/kg?d dose for treatment), 30 cases in each group. The growth and development [height, body weight, growth rate (GV), height standard score (Ht SDS)], bone metabolism [bone alkaline phosphatase (BAP), amino terminal propeptide of procollagen type I (PINP) and cross linked carboxyl terminal peptide of collagen type I (β-CTX)], thyroid function [thyroid stimulating hormone (TSH), free triiodothyronine (FT3/sub>), free thyroxine (FT4/sub>)] and serum Ghrelin, IGF-1 levels were compared between the two groups. Adverse reactions were observed. Results: 1 year after treatment, the height, body weight, GV and Ht SDS in high-dose group were higher than those in low-dose group (P<0.05). 1 year after treatment, BAP and PINP in high-dose group were higher than those in low-dose group, and β-CTX was lower than that in low-dose group (P<0.05). There were no significant differences in TSH, FT3/sub> and FT4/sub> between the two groups at 1 year after treatment (P>0.05). Ghrelin in high-dose group was lower than that in low-dose group, and the level of IGF-1 was higher than that in low-dose group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Compared with the 0.10 U/kg?d dose of rHGH, the 0.20 U/kg?d dose of rHGH can better promote the growth and development of children with ISS, regulate bone metabolism, serum Ghrelin and IGF-1 levels, and which has no effect on human thyroid function. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
